HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer

HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma

(2016) Yanxin Pei et al.   CANCER CELL

Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells

(2016) Zhao-Tong Wang et al.   CELLULAR SIGNALLING

Concepts to Target MYC in Pancreatic Cancer

(2016) M. Wirth et al.   MOLECULAR CANCER THERAPEUTICS

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine

(2015) Claudia Fiorini et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

(2015) E. M. Alexandrova et al.   NATURE

Acetylation site specificities of lysine deacetylase inhibitors in human cells

(2015) Christian Schölz et al.   NATURE BIOTECHNOLOGY

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

(2015) Pawel K Mazur et al.   NATURE MEDICINE

MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies

(2015) E Hessmann et al.   ONCOGENE

KrasG12D induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells

(2015) S Diersch et al.   ONCOGENE

Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery

(2015) Celeste B. Greer et al.   Cell Reports

AKT regulates NPM dependent ARF localization and p53mut stability in tumors

(2015) Garth Hamilton et al.   Oncotarget

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

(2014) Susann Weissmueller et al.   CELL

Pancreatic cancer genomics

(2014) David K Chang et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

A modular and flexible ESC-based mouse model of pancreatic cancer

(2014) M. Saborowski et al.   GENES & DEVELOPMENT

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas

(2014) Roberta Zappasodi et al.   INTERNATIONAL JOURNAL OF CANCER

Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles

(2014) Susanne Walz et al.   NATURE

A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer

(2014) Nina Schönhuber et al.   NATURE MEDICINE

MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib

(2014) Matthias Wirth et al.   NUCLEIC ACIDS RESEARCH

Further Characterization of HDAC and SIRT Gene Expression Patterns in Pancreatic Cancer and Their Relation to Disease Outcome

(2014) Mehdi Ouaïssi et al.   PLoS One

Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells

(2014) Shereen Jamaladdin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

(2014) Joydeep Bhadury et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells

(2014) C Geismann et al.   Cell Death & Disease

The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound

(2014) Jake Shortt et al.   Cell Reports

p53 Acetylation: Regulation and Consequences

(2014) Sara Reed et al.   Cancers

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors

(2013) J Sonnemann et al.   BRITISH JOURNAL OF CANCER

Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer

(2013) Tomer Cooks et al.   CANCER CELL

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

(2013) W Hanel et al.   CELL DEATH AND DIFFERENTIATION

Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability

(2013) Benjamin E. L. Lauffer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade

(2013) Y J Kim et al.   ONCOGENE

The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2

(2013) Olivier Peulen et al.   PLoS One

Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression

(2013) M C C Sachweh et al.   Cell Death & Disease

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

(2013) G M Matthews et al.   Cell Death & Disease

MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors

(2012) Wajana L. Labisso et al.   CELL CYCLE

Mutant p53: one name, many proteins

(2012) W. A. Freed-Pastor et al.   GENES & DEVELOPMENT

Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death

(2012) Laura Conradt et al.   INTERNATIONAL JOURNAL OF CANCER

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8

(2012) W Yan et al.   ONCOGENE

Chromatin-targeting small molecules cause class-specific transcriptional changes in pancreatic endocrine cells

(2012) S. Kubicek et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53

(2011) P. Timpson et al.   CANCER RESEARCH

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

(2011) D Li et al.   CELL DEATH AND DIFFERENTIATION

Transcriptional and epigenetic regulation of the p53 tumor suppressor gene

(2011) Ricardo Saldaña-Meyer et al.   Epigenetics

Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer

(2011) Ali Aghdassi et al.   GUT

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

HDAC1 regulates pluripotency and lineage specific transcriptional networks in embryonic and trophoblast stem cells

(2011) Benjamin L. Kidder et al.   NUCLEIC ACIDS RESEARCH

Emphasizing the positive: A role for histone deacetylases in transcriptional activation

(2010) Oliver M. Dovey et al.   CELL CYCLE

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function

(2010) Asfar S. Azmi et al.   EUROPEAN JOURNAL OF CANCER

p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma

(2010) Brendan Doyle et al.   JOURNAL OF PATHOLOGY

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells

(2010) Susanne Schuler et al.   Molecular Cancer

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects

(2010) G M Marshall et al.   ONCOGENE

Cross talk between stimulated NF-κB and the tumor suppressor p53

(2010) G Schneider et al.   ONCOGENE

A Simple and Cost-Effective Method to Transfect Small Interfering RNAs Into Pancreatic Cancer Cell Lines Using Polyethylenimine

(2010) Matthias Wirth et al.   PANCREAS

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

(2010) James E. Bradner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo

(2009) Annika Lehmann et al.   BMC CANCER

HDACi – Targets beyond chromatin

(2009) Marc Buchwald et al.   CANCER LETTERS

Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes

(2009) Zhibin Wang et al.   CELL

E-Cadherin Regulates Metastasis of Pancreatic Cancer In Vivo and Is Suppressed by a SNAIL/HDAC1/HDAC2 Repressor Complex

(2009) Johannes von Burstin et al.   GASTROENTEROLOGY

HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA

(2009) P Fritsche et al.   GUT

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

(2009) J. P. Morton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutant p53 Gain-of-Function in Cancer

(2009) M. Oren et al.   Cold Spring Harbor Perspectives in Biology

PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations

(2008) Y. Li et al.   CANCER RESEARCH

Genome-Wide Transcriptional Response to 5-Aza-2'-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells

(2008) G. Heller et al.   CANCER RESEARCH

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

(2008) T. Terzian et al.   GENES & DEVELOPMENT

Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells

(2008) X Sui et al.   ONCOGENE